IPP Bureau
Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies
By IPP Bureau - April 04, 2026
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma
By IPP Bureau - April 04, 2026
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Jan Vishwas Bill 2026 decriminalises minor health sector offences, eases compliance burden
By IPP Bureau - April 04, 2026
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
By IPP Bureau - April 03, 2026
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment
By IPP Bureau - April 03, 2026
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData
By IPP Bureau - April 03, 2026
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra
By IPP Bureau - April 03, 2026
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
By IPP Bureau - April 03, 2026
Its a major breakthrough for women’s ovarian cancer care in Europe
Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness
By IPP Bureau - April 03, 2026
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells
By IPP Bureau - April 03, 2026
The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells
Nearly 40 industry groups unite to push for EU Biotech Act II
By IPP Bureau - April 03, 2026
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer
By IPP Bureau - April 03, 2026
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
EMA moves to cut animal testing with “virtual control groups” in preclinical research
By IPP Bureau - April 03, 2026
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Biocytogen and Sihuan Pharmaceutical forge strategic pact to accelerate antibody-based therapies
By IPP Bureau - April 03, 2026
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Cardinal Health boosts production of cutting-edge cancer therapy ingredient
By IPP Bureau - April 03, 2026
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
